BIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 8:15 a.m. PST. The presentation will be accessible via a live webcast on Bio-Techne's Investor Relations website. Bio-Techne specializes in manufacturing purified proteins, reagents, and diagnostic products, generating approximately $1.1 billion in net sales in fiscal 2022. The company employs around 3,000 people globally and offers a wide range of scientific products for molecular diagnostics and biological research.

MINNEAPOLIS, Dec. 21, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 41^st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 8:15 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000 employees worldwide.

Contact:	David Clair, Vice President, Investor Relations
	david.clair@bio-techne.com
	612-656-4416

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-301706971.html

SOURCE Bio-Techne Corporation

FAQ

When will Bio-Techne present at the J.P. Morgan Healthcare Conference?

Bio-Techne will present at the J.P. Morgan Healthcare Conference on January 11, 2023, at 8:15 a.m. PST.

How can I watch Bio-Techne's presentation online?

You can watch Bio-Techne's presentation live via webcast on their Investor Relations website.

What is Bio-Techne's stock symbol?

Bio-Techne's stock symbol is TECH.

What products does Bio-Techne offer?

Bio-Techne offers purified proteins, reagents, diagnostic products, and genomic tools for biomedical and clinical research.

What were Bio-Techne's sales figures for fiscal 2022?

Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022.